Alnylam Pharmaceuticals Inc (DUL.BE)
Chart Events
Performance Outlook
| Previous Close | 173.24 |
| Open | 172.28 |
| Bid | 173.28 x N/A |
| Ask | 174.80 x N/A |
| Day's Range | 172.28 - 174.78 |
| 52 Week Range | 113.36 - 230.45 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Apr 26, 2023 - May 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DUL.BE
Related Research
- InvestorPlace
3 Growth Stocks That Could Disrupt the Healthcare Industry
Healthcare growth stocks are often sought out by investors looking for market disruptors. That’s because these stocks can potentially deliver high revenue growth, earnings, and stock price. As an evolving sector, the healthcare industry is seeing high demand for innovative solutions to high patient costs and technology-driven efficiency. Examples of healthcare growth stocks include pharmaceutical companies developing new drugs, medical device manufacturers creating innovative devices, and health
- CNW Group
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.
- Business Wire
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
CAMBRIDGE, Mass., March 08, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience.
